Features of the ViewRay system, which is designed for the treatment of cancer, include continuous soft-tissue imaging and the combination of radiotherapy delivery and simultaneous magnetic resonance imaging.
“FDA clearance of our integrated system is a major milestone in the development of our technology,” said ViewRay President and CEO Gregory M. Ayers, MD, PhD, in the release. “It has already been an exciting year for ViewRay, with an additional round of funding and the installation of our first research systems at major U.S. medical centers. Early clinical imaging studies have verified the quality of the system’s MR images, and now we’re looking forward to clinical applications.”
ViewRay is headquartered in Oakwood Village, Ohio.
Related Articles on FDA Clearances:
ETView Medical Receives FDA 510(k) Clearance for Line of Innovative Airway Devices
Medspira Receives FDA 510(k) Clearance for Anorectal Manometry Device
MAQUET Cardiovascular Receives FDA 510(k) Clearance for New Intra-Aortic Balloon Catheter Sizes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
